EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2012 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Agreement (this “Agreement”), effective as of November 1, 2011 (the “Effective Date”), by and between TG Therapeutics, Inc., a Delaware corporation with an address at 787 Seventh Avenue, New York, NY 10019 (the “Company”), and SEAN A. POWER, having a mailing address at 14 Pokahoe Drive, Sleepy Hollow, NY 10591 (the “Executive”).
RESTRICTED STOCK SUBSCRIPTION AGREEMENTRestricted Stock Subscription Agreement • March 14th, 2012 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS RESTRICTED STOCK SUBSCRIPTION AGREEMENT (“Agreement”) is dated as of November 15, 2011, by and between the undersigned (the “Purchaser”) and TG Therapeutics, Inc., a Delaware corporation with a place of business at 787 Seventh Avenue, 48th Floor, New York, NY 10019 (the “Corporation” or “Company”).
EXCLUSIVE LICENSE AGREEMENT BY AND AMONG GTC BIOTHERAPEUTICS, INC., LFB BIOTECHNOLOGIES S.A.S., LFB/GTC LLC and TG THERAPEUTICS, INC. January, 30th , 2012 CONFIDENTIALExclusive License Agreement • March 14th, 2012 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of January 30th, 2012 (the “Effective Date”) by and among GTC Biotherapeutics, Inc., a Massachusetts corporation with a principal place of business at 175 Crossing Boulevard, Framingham, Massachusetts 01701 (“GTC”), LFB Biotechnologies S.A.S., a company organized under the laws of France with a principal place of business at 3 avenue des Tropiques, B.P. 305-Les Ulis- 91958, Courtaboeuf Cedex, France (“LFB”), LFB/GTC LLC, a New York limited liability company with a principal place of business at 175 Crossing Boulevard, Framingham, Massachusetts 01701 (“LFB/GTC” and, collectively with GTC and LFB, “LICENSOR”) and TG Therapeutics, Inc., a Delaware corporation with a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (“TG”). Each of TG and LICENSOR is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
WARRANT TO PURCHASE COMMON STOCK OF Manhattan Pharmaceuticals, Inc.Warrant Agreement • March 14th, 2012 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, [Name of Holder], having an address at [_______________________] (the “Investor”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Manhattan Pharmaceuticals, Inc., a Delaware corporation, (the “Company”) at any time during the period commencing on the Initial Exercise Date (as herein defined) and ending at 5:00 p.m., Eastern time, on _____, 201_ (the “Expiration Date”), [________] shares of the Common Stock (as herein defined), in accordance with the terms thereof (as such number may be adjusted as provided herein, the “Warrant Shares”), subject to the provisions and upon the terms and conditions hereinafter set forth in this Warrant (“Warrant”). This Warrant is being issued pursuant to the terms of the Subscription Agreement, dated as of _____, 201_, as amended, by and among the Company, the original Investor and the other parties named therein (the “Purchase Agreement”).
